Journal of Pharmacokinetics and Pharmacodynamics

With 2025 comes a major change to the journal - we are going completely online! No longer will we have articles waiting in limbo for them to be assigned to an issue and physically published. All accepted articles, after galley proofs are complete, will be available online in the 2025 volume. Already there are a dozen papers posted for the year. And just a reminder - we have 2 on-going themed issues: * Catalyzing Change in MID3 through Globalization, Education, and Innovation * ICH E14 - 20 Years of Assessing QT Prolongation With the change in being online, articles for these themed issues will be published as they are accepted, so check back regularly for new updates. Here's to a great 2025!

Update on the Strategic Alliance Between ISoP and JPKPD: In 2012, a strategic alliance was formed between the Journal of Pharmacokinetics and Pharmacodynamics (JPKPD) and the International Society of Pharmacometrics (ISoP) making JPKPD “an official journal of ISoP”. Since then, JPKPD published abstracts from early ACoP meetings, published society news, updates from working groups, themed issues around the recent advances in pharmacometrics, and commentaries from thought leaders. Today, we wish to announce the dissolution of that alliance. Effective immediately, JPKPD will no longer be associated with the society. The decision comes as ISoP reevaluates their long-term goals and priorities as a society and how to best provide value to its members. Those members who receive JPKPD as a member benefit from ISoP will need to transition to a subscription to continue access to the journal.  We wish ISoP the best as they move forward as a society. #ISoP #JPKPD

In 2025, the ICH E14 guidance turns 20 years old. Andreas Krause at Simulations Plus will be guest editing a themed issue of the journal dedicated to E14 entitled "ICH E14 - 20 years of assessing QT prolongation". The topics reflect the breadth of current research activities, spanning preclinical assessments, clinical study conduct, ECG evaluation, data analysis, concentration-QT modeling, health authority assessments, and more. Position papers, reviews, tutorials, methodology, and case studies are planned. If you would like to contribute to the journal you can contact Andreas through LinkedIn. You can find the themed issue at: https://lnkd.in/gf5naC-K As the journal transitions to an online format, this allows us to publish articles as they are received, so check back regularly for new articles. Currently more than a dozen articles are planned for the issue. Thanks Andreas and to the contributors for their help in bringing this to fruition.

JPKPD is proud to have supported the 2024 ACoP Student Communication Challenge. Each of the participants had the daunting challenge of presenting their doctoral research in 4 slides, 4 minutes, with no text on the slides. Their coaches did a great job as all the participants did an amazing job. Congratulations to the winners: Yufei Shi, Joo Young Na, Se Jin Kim, and Joseph Cave. Well done. ISoP will be presenting each of you with a $500 honorarium courtesy of the journal. I wonder what the challenge will be next year. #ACoP #ISoP #JPKPD #Communication

The October and December issues of the Journal of Pharmacokinetics and Pharmacodynamics has been issued. The October issues is a dual themed issue: * PBPK of Novel Modalities. This has been guest edited by Robert Bies and Arian Emami Riedmaier. * Assessing QSP Models and Amplifying their Impact. This has been guest edited by Abhishek Gulati and Jessica Brady. I want to thank all the contributors and editors for these two great themed issues. Please check them out. The December issue is in memoriam to Dr Tom Ludden, a quiet pioneer and leader in pharmacometrics. Some might argue that without Tom, the field would not be where it is today, and I agree with that. He will be missed. Starting in 2025, JPKPD will be online only as Springer transitions to online journal formats only. The December issue is packed with over 25 articles as we clear our print queue in anticipation for our online format.

The June issue of the Journal of Pharmacokinetics and Pharmacodynamics has been released. In this issue, Ramanathan and colleagues at SUNY Buffalo evaluate chatGPT to see how well it can be used to develop models in NONMEM. Also in this issue are a number of original reports: · A semi-mechanistic model of resistance development to β-lactam and β-lactamase-inhibitor combinations; · How drug onset rate and duration of action affect drug forgiveness; · A PopPK model of balovaptan to support dose selection in adult and pediatric populations; · PopPK of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension; · Subgroup identification-based model selection to improve the predictive performance of individualized dosing; · Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis; · Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing; and · Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. The editors would like to thank all the reviewers and authors for their help in making this issue a success.

The April Issue of the Journal of Pharmacokinetics and Pharmacodynamics has just been printed. In this issue, there are two great commentaries: * ISoP presents some highlights from ACOP14. * Shin and Ramanathan examine how well chatGPT does at solving PK-related queries. For the original articles in this issue: * Ronchi and colleagues present a genetic algorithm search method for covariate identification in PopPK; * Bram and colleagues present the neural ODE algorithm and how it can be used in pharmacometrics; * Yu and colleagues present the PopPK-PD analysis of efmarodocokin alfa (IL-22c); * Wahlquist and colleagues present how to determine the structure of a covariate model using symbolic regression networks; and * Huber and Mistry show how to link in vitro-in vivo correlations from preclinical studies to a clinical semimechanistic model of tumor growth. Check it out! As always, I would like to thank the reviewers and authors who contributed to making this issue a success!!

The February issue of the Journal of Pharmacokinetics and Pharmacodynamics has been released. In this issue I take a deep dive into the world of plagiarism and find it to be a mess. It's one of those things that you think you know, but when you start reading about it, you realize how little you actually did know. There is also a collaborative commentary from leading industry, academic, and clinical experts on training the next generation of pharmacometricians. Original research articles include: Wang and colleagues present a short communication on optimal sampling in data rich designs; White and colleagues apply classical structural identifiability concepts to ligand-binding interactions; Brekkan and colleagues analyze anti-drug antibodies to certolizumab pegol using a mixed hidden Markov model; and Jiang and colleagues present the population PK and PD of nifekalant in Chinese volunteers. Check it out! https://lnkd.in/g8xZXPCc